Reports Q1 revenue $210M, consensus $169.7M. “We are off to a strong start in 2024, with outstanding commercial performance and achievement of all planned clinical and regulatory milestones for the first quarter,” said Matthew Klein, M.D., Chief Executive Officer, PTC Therapeutics, Inc. “We remain on track to achieve the many planned 2024 clinical and regulatory milestones, including global regulatory submissions for sepiapterin.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- PTC Therapeutics submits MAA for sepiapterin in PKU to EMA
- Cantor Fitzgerald biotech analyst holds an analyst/industry conference call
- PTC Therapeutics provides regulatory updates
- PTC Therapeutics price target raised to $28 from $22 at RBC Capital
- PTC Therapeutics price target lowered to $30 from $32 at TD Cowen
